Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
96.95
-1.25 (-1.27%)
At close: Jan 30, 2026, 4:00 PM EST
97.90
+0.95 (0.98%)
After-hours: Jan 30, 2026, 7:56 PM EST
Revolution Medicines Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
809
Market Cap
18.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 11.58M | -23.80M | -67.27% |
| Dec 31, 2022 | 35.38M | 5.99M | 20.38% |
| Dec 31, 2021 | 29.39M | -13.59M | -31.62% |
| Dec 31, 2020 | 42.98M | -7.06M | -14.10% |
| Dec 31, 2019 | 50.04M | 29.88M | 148.16% |
| Dec 31, 2018 | 20.17M | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 4.81B |
| Genmab | 3.85B |
| BioNTech SE | 3.70B |
| Royalty Pharma | 2.35B |
| Moderna | 2.23B |
| Ionis Pharmaceuticals | 966.96M |
| Ascendis Pharma | 758.59M |
| Madrigal Pharmaceuticals | 740.64M |
RVMD News
- 1 day ago - Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance - Seeking Alpha
- 4 days ago - Revolution Medicines Stock Sinks After Merck Deal Talks Collapse - Benzinga
- 5 days ago - Merck no longer in talks to buy Revolution Medicines, WSJ reports - Reuters
- 5 days ago - Merck No Longer in Talks to Buy Revolution Medicines - WSJ
- 18 days ago - Revolution Medicines, Inc. (RVMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 21 days ago - Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion - WSJ
- 21 days ago - Revolution Medicines: "Strong Buy" As Acquisition Prospects Continue To Circle - Seeking Alpha
- 21 days ago - Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges. - Barrons